New Treatment Option for Spinal Muscular Atrophy with Dr. Greg Rippon Genentech TRANSCRIPT

Dr. Greg Rippon, Vice President and Chief Medical Partner of Neurology, Genentech shines light on SMA, spinal muscular atrophy, a severe inherited progressive neuromuscular disease and one of the most common rare diseases affecting babies. With the introduction of Evrysdi to the treatment options for SMA, an oral treatment is being tested to increase the production of the functional survival motor neuron protein and thus benefit patients in their motor functioning.

@genentech #genentech #SMA #SpinalMuscularAtrophy #Evrysdi #raredisease

Listen to the podcast here.

Share on facebook
Share on twitter
Share on linkedin
Related Post


Sign up for Breaking News, Newsletter, Blog Posts and Special Deals from 1631 Digital and their media/marketing partners.

Subscribers agree to be contacted from 1631 Digital News and/or their media/marketing partners for breaking news alerts, newsletters and special media marketing offers via email, mail and/or texting communication.